House leaders want probe on 'detrimental' DoH, FDA policies for Covid-19 drug registration

AT least two leaders of the House of Representatives are seeking an inquiry into the policies of the Department of Health (DoH) and the Food and Drug Administration (FA) for the use and approval of drug products for the coronavirus disease 2019 (Covid-19).

Speaker Lord Allan Velasco and Deputy Speaker Bernadette Herrera-Dy filed House Resolution (HR) 1711 that calls on the Committee on Good Government and Public Accountability to look into the policies and guidelines for the registration, utilization, [manufacturing], distribution, and sale of drug products "which appear to be detrimental to public interest".